Los Angeles Capital Management LLC Boosts Stock Holdings in Doximity, Inc. (NASDAQ:DOCS)

Los Angeles Capital Management LLC increased its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 6,242.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 650,874 shares of the company's stock after purchasing an additional 640,612 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.35% of Doximity worth $28,359,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of DOCS. LRI Investments LLC bought a new stake in shares of Doximity in the 1st quarter worth approximately $27,000. Farther Finance Advisors LLC raised its holdings in shares of Doximity by 324.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company's stock worth $34,000 after purchasing an additional 603 shares during the period. Blue Trust Inc. raised its holdings in shares of Doximity by 621.4% in the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the company's stock worth $37,000 after purchasing an additional 1,193 shares during the period. Quarry LP raised its holdings in shares of Doximity by 101.2% in the 2nd quarter. Quarry LP now owns 1,616 shares of the company's stock worth $45,000 after purchasing an additional 131,253 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Doximity in the 1st quarter worth approximately $46,000. Institutional investors own 87.19% of the company's stock.

Analyst Upgrades and Downgrades

DOCS has been the topic of a number of analyst reports. Baird R W raised shares of Doximity to a "strong-buy" rating in a report on Tuesday, September 17th. Bank of America boosted their target price on shares of Doximity from $32.00 to $45.00 and gave the company a "neutral" rating in a report on Monday, October 7th. Robert W. Baird boosted their target price on shares of Doximity from $41.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, September 17th. Raymond James reissued an "outperform" rating and set a $65.00 target price (up previously from $37.00) on shares of Doximity in a report on Friday. Finally, KeyCorp raised shares of Doximity from a "sector weight" rating to an "overweight" rating and set a $70.00 target price on the stock in a report on Friday. One analyst has rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $45.69.

Doximity Trading Up 5.2 %

Shares of DOCS traded up $3.00 during mid-day trading on Monday, reaching $61.25. 5,349,238 shares of the stock traded hands, compared to its average volume of 1,710,653. The firm has a fifty day moving average price of $42.04 and a 200 day moving average price of $33.44. The company has a market cap of $11.37 billion, a price-to-earnings ratio of 70.40, a price-to-earnings-growth ratio of 7.00 and a beta of 1.30. Doximity, Inc. has a 1 year low of $22.96 and a 1 year high of $61.75.

Doximity (NASDAQ:DOCS - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.06. Doximity had a net margin of 33.69% and a return on equity of 20.17%. The company had revenue of $126.68 million during the quarter, compared to analyst estimates of $119.88 million. On average, sell-side analysts anticipate that Doximity, Inc. will post 0.8 EPS for the current year.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.